Diaformin XR

Quick links

Choose a section

Quick links to important sections

Advertisements

Diaformin XR

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Diaformin XR

Property Description
Active Ingredient Metformin Hydrochloride
Form Extended-Release Tablet (Oral Solid)
Pharmacological Class Biguanide Class (Oral Antihyperglycemic Agent)
Common Use Management of Type 2 Diabetes Mellitus
Origin Synthetic derivative (of the natural product guanidine)

Diaformin XR is a prescription-only medicine and an oral formulation developed as a first-line drug for the chronic management of Type 2 Diabetes Mellitus in adults. It is classified as an Oral Antihyperglycemic Agent designed to help patients achieve stable blood glucose control and mitigate the effects of high blood sugar, known as hyperglycemia.


Definition and Pharmacological Classification

Diaformin XR, containing the active ingredient Metformin, belongs to the Biguanide class of medicines. This class is widely used as a cornerstone pharmacotherapy for managing Type 2 Diabetes Mellitus. Its application in treatment reflects its established role in the regulation of blood sugar.

This medication functions as a systemic agent that acts throughout the body to normalize metabolic function, which is often impaired by reduced cellular response to the hormone insulin. The active ingredient, Metformin, has a long-standing role in clinical practice.


Composition and the Extended-Release (XR) Form

The sole active ingredient in Diaformin XR is Metformin Hydrochloride, a compound chemically identified as a Dimethylbiguanide. Metformin is a synthetic derivative derived from the structure of guanidine. The "XR" designation is a key differentiating feature, signifying its Extended-Release Tablet form, which is a modified-release formulation. This dosage form is distinct because the drug is contained within a specialized polymer matrix system, designed to control the dissolution rate and ensure that Metformin is released slowly and continuously over a prolonged period. This controlled delivery mechanism is designed to provide more stable plasma concentrations compared to traditional immediate-release versions.


General Therapeutic Purpose and Action

The general purpose of Diaformin XR is to stabilize high blood sugar by regulating three core processes related to glucose management. The medication works by acting as an antihyperglycemic agent that primarily reduces the amount of glucose produced by the liver and enhances the sensitivity of muscle and fat cells to insulin. These actions are essential for correcting the metabolic imbalances in Type 2 Diabetes Mellitus, providing effective, sustained blood glucose control.

Advertisements

What side effects are possible with Diaformin XR?

Possible side effects and safety information

Official Adverse Reaction Scope

The medicine's safety profile is documented based on frequency and system-organ class groupings in official regulatory labeling. Gastrointestinal disorders are classified as very common adverse reactions. These effects, which include diarrhoea, nausea, vomiting, and abdominal pain, along with a metallic taste (taste disturbance), are generally most frequent at the start of treatment.

Common adverse effects are documented as a decrease in Vitamin B12 levels, which has been associated with long-term use and can potentially lead to megaloblastic anaemia.

Serious Adverse Reactions and Restrictions

The most serious, though rare, adverse reaction listed is lactic acidosis, a metabolic complication requiring immediate attention. This risk is central to the drug's regulatory constraints and is the primary reason the medicine is contraindicated in specific patient populations.

Safety limitations explicitly state that the drug should not be used in individuals with severe renal impairment, significant hepatic impairment, or certain acute cardiac or metabolic conditions. These constraints are based on the documented risk factors for lactic acidosis.

Population and Contextual Safety

Regulatory documents emphasize that the risk of lactic acidosis is increased in older adults and is closely tied to the patient's renal function. The label also notes that excessive alcohol intake and certain medical procedures, such as those involving intravascular iodinated contrast agents, can elevate the risk and require specific safety considerations, including temporary discontinuation of the medicine.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile establishes that the most serious consequence of Diaformin XR (Metformin) overdose is the development of lactic acidosis, a life-threatening metabolic emergency. Initial documented presentations may include non-specific signs such as nausea, vomiting, diarrhea, abdominal pain, and general malaise. As the condition worsens, symptoms can progress to severe manifestations including hypothermia, low blood pressure (hypotension), and decreased consciousness or coma.

Required Emergency Actions

Overdose Component Official Regulatory Statement
Life-Threatening Outcome Lactic Acidosis is classified as a medical emergency requiring immediate attention.
When to Seek Help The patient must seek immediate medical attention upon suspicion of overdose or the onset of any symptom suggestive of lactic acidosis.
Antidote Availability There is no specific antidote known for Metformin overdose.

Management of an overdose requires the immediate institution of supportive measures in a hospital setting. Due to the drug’s ready dialyzability, prompt hemodialysis is the specific procedure officially described for effectively clearing Metformin from the body and correcting severe acidosis. Official labeling notes that the risk of accumulation and lactic acidosis is significantly increased in patients with pre-existing renal impairment or hepatic impairment.

Advertisements

Therapeutic Uses of Diaformin XR

Quick Facts: Main Uses and Benefits

  • Therapeutic Domain: May help manage blood glucose (sugar) levels.
  • Primary Use: Used to assist in the treatment of Type 2 Diabetes Mellitus in adults.
  • Role in Therapy: Generally prescribed when physical activity and dietary adjustments alone are insufficient for maintaining adequate blood sugar control.
  • Combination Use: May be utilized as a standalone therapy or in combination with other oral antidiabetic agents, or with insulin, as determined by a healthcare provider.

What Diaformin XR Treats: Main Uses and Benefits

Diaformin XR is a prescription medication utilized in the care of Type 2 Diabetes Mellitus in adult patients. The primary goal of therapy is to help reduce and manage high blood glucose levels (hyperglycemia) when lifestyle interventions, such as changes in diet and regular physical activity, do not achieve the desired clinical result.

This medication is frequently considered a foundational component of treatment, particularly for individuals who are also managing weight, in conjunction with continued lifestyle modifications. Diaformin XR may be an appropriate therapeutic option for use alone (monotherapy) or it may be combined with other medications intended to manage blood sugar, including certain other oral agents or injected insulin. The use of this medication aims to support stable blood sugar readings, which may help lessen the potential for long-term health complications associated with uncontrolled high glucose levels.

Advertisements

Eligibility and Restrictions for Use

The eligibility for using Diaformin XR (Metformin Extended-Release) is strictly governed by official regulatory documents, primarily focusing on avoiding the risk of lactic acidosis. The medicine is approved for use in adults (age 18 and older) diagnosed with Type 2 Diabetes Mellitus.


Contraindications (Who Must Not Use)

Diaformin XR is absolutely contraindicated in patients with the following conditions:

  • Severe Renal Impairment: Defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2.
  • Metabolic Acidosis: Including diabetic ketoacidosis (DKA).
  • Hypersensitivity: Known allergy to Metformin Hydrochloride or its components.
  • Acute Conditions: States like acute alcohol intoxication or decompensated heart failure that may cause tissue hypoxia.

Restricted and Conditional Use

Use is limited or requires special consideration in specific populations:

  • Moderate Renal Impairment: Initiation is not recommended if eGFR is between 30 to 45 mL/min/1.73 m^2.
  • Hepatic Impairment: Use should generally be avoided due to increased risk of lactic acidosis.
  • Age: The safety and effectiveness of this extended-release formulation are not established for patients younger than 18.
  • Procedures: The medicine must be temporarily discontinued before certain surgical procedures or radiologic studies involving iodinated contrast agents.
  • Pregnancy/Lactation: Use during these periods is only permitted if the benefit outweighs the potential risk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diaformin XR (Metformin Hydrochloride) interacts primarily through effects on renal clearance and through pharmacodynamic influence on blood glucose control, as documented in regulatory sources.

Mandatory Restrictions and Contraindicated Combinations

Co-administration with iodinated contrast agents requires the mandatory temporary withholding of Diaformin XR before and for at least 48 hours after the procedure, only resuming once renal function is confirmed as stable. Excessive alcohol intake is associated with a significantly increased risk of lactic acidosis and is officially warned against.

Exposure-Modifying and Transporter Interactions

Certain cationic medicines, such as Cimetidine, Dolutegravir, and Vandetanib, are documented to increase Metformin's plasma exposure. This occurs because these substances inhibit the Organic Cation Transporters (OCT2/MATE) responsible for Metformin's elimination via the kidney. Other cationic drugs are listed as potential competitors for these transport systems. The extended-release formulation's systemic exposure (AUC) is increased by approximately 50% when administered with food.

Pharmacodynamic and Metabolic Considerations

Metformin co-administered with other glucose-lowering agents (e.g., insulin, sulfonylureas) has an additive effect, increasing the risk of hypoglycemia. Conversely, drugs with intrinsic hyperglycaemic activity, such as glucocorticoids and thiazide diuretics, may counteract Metformin’s effect. Long-term Metformin use is associated with a regulatory-documented reduction in serum Vitamin B12 levels, requiring monitoring. Interaction risk is heightened in patients with impaired renal or hepatic function.

Advertisements

Mechanism of Action

Modulating Hepatic Glucose Output

The mechanism of action for Diaformin XR (metformin) focuses on modulating the body’s core metabolic pathways that influence blood glucose concentration, operating through three complementary biological domains. The primary action involves partially inhibiting Mitochondrial Complex I in the liver. This molecular interaction activates the energy sensor AMP-activated protein kinase (AMPK), which subsequently suppresses the pathway responsible for synthesizing new glucose (gluconeogenesis). This cascade results in a modulation of the physiological system by reducing the release of glucose from the liver into the bloodstream.


Enhancing Peripheral Glucose Utilization

Metformin functions as an insulin sensitizer, meaning its mechanism modulates the body's cellular response to its own insulin. AMPK activation in muscle and fat cells promotes the translocation of the GLUT4 transporter to the cell surface. This promotes the tissues' ability to draw glucose from the circulation, resulting in peripheral glucose clearance and overall utilization. This systemic effect, along with a minor reduction in intestinal glucose absorption, leads to an integrated metabolic constraint. The mechanism is functionally dependent on the presence of some circulating insulin and is confined to suppressing glucose output and enhancing sensitivity.

Advertisements

Dosage and Administration Information

How to Use Diaformin XR

Diaformin XR (Metformin Extended-Release) is prescribed for chronic use and is used according to specific administration protocols. The medicine is intended for oral administration only and follows a once-daily dosing schedule.


Administration Protocol and Dosage

Metformin Extended-Release tablets must be swallowed whole and must never be crushed, cut, or chewed, as the integrity of the extended-release formulation is essential for proper function. The dose is consistently taken with the evening meal to help maintain stable systemic drug concentrations.

Therapy typically begins with a starting dose of 500 mg once daily. Based on the patient's documented blood glucose control, the dosage may be adjusted in increments of 500 mg over weekly or bi-weekly intervals. The maximum daily dose for this once-daily regimen is 2,000 mg.


Use Constraints in Specific Populations

Clinical protocols include specific considerations regarding kidney function. Use of the drug is contraindicated when the estimated Glomerular Filtration Rate (eGFR) falls below 30 mL/min/1.73 m^2. Furthermore, initiating treatment is not recommended if the eGFR is between 30 to 45 mL/min/1.73 m^2. For older adults, clinical practice necessitates more frequent assessment of renal function.

If a dose is missed, the patient must not take two doses on the same day; the missed dose should be skipped, and the patient should resume the usual schedule at the next designated time.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diaformin XR

Evidence for Diaformin XR as a First-Line Treatment

Research has examined the use of Diaformin XR (metformin extended-release) as a starting treatment for adults with Type 2 Diabetes. The evidence base primarily relies on Randomized Controlled Trials (RCTs), where the medicine was studied for its impact on blood sugar markers, including Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG). Regulatory approval often relies on additional research that aimed to assess its physiological similarity (bioequivalence) compared to the immediate-release version. Long-term research on the active ingredient (metformin IR) has described patterns related to the occurrence of microvascular and macrovascular events over many years.

Evidence in Combination Therapy and Formulation Comparison

Diaformin XR was evaluated in RCTs exploring its use alongside other antidiabetic agents. These studies monitored changes in key markers and described the consistent inclusion of the medication within combination regimens. Dedicated comparative trials have explored differences between the XR and immediate-release (IR) formulations and reported a pattern of differences in the recording of Gastrointestinal (GI) adverse events between the two formulations in certain patient cohorts.

Key Limitations and Areas of Research Uncertainty

What remains uncertain includes the specific long-term impact of the Diaformin XR formulation itself on major health outcomes, such as vascular complications. While the evidence supporting the general use of metformin is based on an extensive research record, comparative evidence is lacking for the specific long-term outcomes of the XR formulation. Furthermore, data for highly specific groups, such as children, pregnant individuals, or those with advanced kidney disease, remain insufficient to draw conclusions from the research record.

Key Studies & References

  1. Metformin and Extended-Release Metformin: Efficacy, Safety, and Patient Compliance (Systematic Review/Meta-analysis)
  2. WHO Model List of Essential Medicines (Used to establish long-term general acceptance/use of the active ingredient)
  3. Public Assessment Report (PAR) for Metformine HCl prolonged-release tablets (Used for bioequivalence and regulatory context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Diaformin XR (FAQ)

Q: Is Diaformin XR a type of insulin?

Diaformin XR is classified as an oral antihyperglycemic agent belonging to the Biguanide class of medicines. According to official product information, its mechanism of action is distinct from that of insulin, and it does not typically produce hypoglycemia (low blood sugar) when used by itself.

Q: Why is Diaformin XR prescribed as an 'XR' tablet?

The 'XR' stands for extended-release. This formulation is designed to release the active ingredient slowly over a prolonged period. The extended-release formulation allows for a once-daily dosing schedule, as documented in official labeling, and studies have also examined its use in patients who may experience gastrointestinal intolerance with the immediate-release version.

Q: Does Diaformin XR help with weight loss?

The medicine is indicated for improving glycemic control (blood sugar) as an adjunct to diet and exercise. It is not indicated for weight loss. Clinical trial data regarding effects on body weight vary, often showing minor mean weight changes.

Q: Why do doctors prescribe this medicine instead of others?

The active ingredient in Diaformin XR is consistently recommended in major clinical guidelines as the first-line pharmacological treatment and the cornerstone pharmacotherapy for managing Type 2 Diabetes Mellitus. This widespread recommendation indicates its established role as a foundation in the standard of care for regulating blood sugar.

Q: Can Diaformin XR be used for conditions other than diabetes?

The only condition for which Diaformin XR is indicated in regulatory labeling is the management of Type 2 Diabetes Mellitus in adults. Official labeling restricts the indicated use of the medicine only to this condition.

Q: How long after starting Diaformin XR do people typically notice an effect?

Stable plasma concentrations of the medicine are typically reached within 24 to 48 hours of administration. Dosage is adjusted based on documented blood glucose control, which usually happens in increments every one to two weeks.

Q: What kind of side effects are most common with Diaformin XR?

According to official product information, the most commonly documented adverse reactions are classified as very common and are generally related to the gastrointestinal system. These include diarrhoea, nausea, vomiting, abdominal pain, and a metallic taste. These effects are usually most frequent when treatment is first initiated.

Q: Are there any common foods or drinks that interact badly with Diaformin XR?

Regulatory documents contain a specific and strict warning against excessive alcohol intake due to an increased risk of a rare, serious metabolic complication. No other common foods or non-alcoholic drinks are listed in regulatory sources as having mandatory restrictions or interactions.

Q: Is Diaformin XR suitable for people with heart problems?

Use of the drug is contraindicated (must not be used) in acute conditions that may cause tissue hypoxia (low oxygen levels in the tissue), such as decompensated heart failure (severe heart failure). The contraindication is based on documented risk factors for a serious metabolic complication.

Q: Does having liver issues mean I can't take Diaformin XR?

Regulatory documents advise that use of the medicine should generally be avoided in patients with hepatic impairment (liver issues). This constraint is based on the increased risk of a serious metabolic complication.

Q: Can Diaformin XR affect my energy levels?

Symptoms of the rare, serious side effect, lactic acidosis, can include non-specific reactions such as malaise (a general feeling of discomfort) and somnolence (drowsiness). These symptoms are included in the description of the rare, serious adverse event.

Q: Is there a generic version of Diaformin XR available?

Yes, the active ingredient in Diaformin XR, Metformin Hydrochloride Extended-Release, is available as a generic medicine from various manufacturers. Diaformin XR is one of several brand names for this formulation.

Q: Does Diaformin XR work differently from other medicines for blood sugar?

Regulatory labeling describes Diaformin XR's mechanism of action as an antihyperglycemic agent that works to decrease glucose production by the liver and improve the body's response to insulin. It is noted to be pharmacologically different from other classes of oral agents.

Q: What is the difference between Diaformin XR and other metformin products like Glucophage?

Diaformin XR is one of several brand names, alongside others like Glucophage XR, that contain the same active ingredient: metformin hydrochloride extended-release. The differences are in the non-active ingredients used by different manufacturers.

Q: How long does Diaformin XR stay in your system after stopping it?

Pharmacokinetic data indicates the medicine's elimination half-life in the plasma is approximately 6.2 hours, and the half-life in the blood is approximately 17.6 hours. The half-life describes the time it takes for half of the substance to be eliminated from the body.

Q: Does Diaformin XR affect cholesterol levels?

Clinical trial data has examined the effects of the active ingredient on lipid parameters. Studies show mean percent changes in Total Cholesterol, Total Triglycerides, LDL-Cholesterol (bad cholesterol), and HDL-Cholesterol (good cholesterol).

Q: Can Diaformin XR cause hypoglycemia (low blood sugar)?

Metformin used alone does not typically cause hypoglycemia (low blood sugar). However, official product information indicates there is an increased risk of hypoglycemia when Diaformin XR is used in combination with insulin and/or an insulin secretagogue (another type of diabetes medicine).

Q: Is Diaformin XR known to be safe during pregnancy?

Regulatory documents state that use during pregnancy is only permitted if the potential benefit justifies the potential risk to the fetus. The decision to use this medicine during pregnancy is documented as being based on whether the potential benefit justifies the potential risk to the fetus.

Q: Can men or women who are planning to conceive continue taking Diaformin XR?

For premenopausal females, regulatory labeling advises that improved blood sugar control may lead to restored ovulation. Patients in this group should be advised of the potential for an unintended pregnancy.

Q: What is the reason Diaformin XR is taken once a day?

The once-daily schedule is possible because the 'XR' (extended-release) formulation is specifically designed to control the dissolution rate. This specialized delivery ensures the active ingredient is released slowly and continuously over a prolonged period.

Q: What is the typical timeframe for getting blood tests while on Diaformin XR?

Official information specifies monitoring timeframes: renal function is assessed prior to starting and periodically thereafter; hematologic parameters (blood counts) are measured annually; and Vitamin B12 levels are assessed at two- to three-year intervals.

Q: How is Diaformin XR eliminated from the body?

The medicine is not metabolized by the liver; it is primarily eliminated unchanged from the body via the renal route, meaning it is excreted through the kidneys.

Q: Does taking Diaformin XR mean I don't have to change my diet?

No. Diaformin XR is indicated as an adjunct to, or in addition to, diet and exercise to improve blood sugar control. The medicine works as part of a complete management plan.

Q: What research evidence supports the use of Diaformin XR?

Research evidence includes Randomized Controlled Trials (RCTs) that examined its impact on blood sugar markers like Glycated Hemoglobin (Hb1c). Studies also assessed its physiological similarity (bioequivalence) compared to the immediate-release version.

Q: Is Diaformin XR considered a 'front-line' treatment for diabetes?

The active ingredient in Diaformin XR is consistently recommended in major clinical guidelines as the cornerstone pharmacotherapy and a first-line drug for the chronic management of Type 2 Diabetes Mellitus.

Q: Is Diaformin XR the same thing as regular metformin?

The active ingredient is the same: metformin hydrochloride. The difference is the extended-release (XR) formulation, which uses a specialized polymer matrix to release the medicine slowly and continuously over a prolonged period.

Q: Is it normal to have some minor stomach upset when first starting Diaformin XR?

Gastrointestinal disorders, such as diarrhoea, nausea, and abdominal pain, are classified as very common adverse reactions. Official documents note that these effects are generally documented as being most frequent at the start of treatment.

Q: Can older adults safely use Diaformin XR?

For older adults, the risk of lactic acidosis is documented as being increased in this population. Therefore, clinical practice necessitates more frequent assessment of renal function for this group.

Q: Does Diaformin XR cause vitamin B12 deficiency?

Long-term use is associated with a regulatory-documented reduction in serum Vitamin B12 levels, which is a documented common adverse effect. This change can potentially lead to megaloblastic anaemia.

Q: What happens if I miss a dose of Diaformin XR?

If a dose is missed, regulatory instructions specify that the missed dose should be skipped entirely. The patient should then resume the usual schedule at the next designated time, and must not take two doses on the same day.

Q: Why is the XR formula sometimes better for people's stomach?

The extended-release formulation provides more stable plasma concentrations compared to the immediate-release version. Comparative trials have reported a pattern of fewer gastrointestinal (GI) adverse events in certain patients using the XR formulation.

Q: Is Diaformin XR supposed to be taken with food?

The medicine is consistently taken with the evening meal. This is done because administration with food has been shown to increase the systemic exposure (AUC) of the medicine, which helps ensure the intended effect is achieved.

Advertisements

How should Diaformin XR be stored and disposed of?

How to Store and Dispose of Diaformin XR

Diaformin XR (metformin hydrochloride extended-release) must be stored under specific environmental and packaging conditions to maintain product quality, as detailed in regulatory labeling.


Official Storage Conditions

Requirement Details
Temperature Store at Controlled Room Temperature, typically 20 to 25 C (68 to 77 F), or below 30 C (86 F).
Protection Keep the medicine in its original container, such as the blister pack, and store in a dry place to prevent degradation.
Safety The product must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Unused or expired Diaformin XR should not be flushed down a toilet or sink, as this is generally restricted by regulatory guidance. The preferred method for disposal is to return the medicine to an authorized location, such as a pharmacist or a community drug take-back program. If no take-back option is available, the medication should be mixed with an undesirable substance, placed in a sealed container, and then discarded in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diaformin XR found in:

A-Z Index: